Jim Cramer says executive embarrassment and presidential candidate tweets won’t solve the EpiPen problem. » Read More
Did you predict that oil would bounce in 2016? Nice! Did you attempt to cash in by buying the biggest oil ETF? Uh-oh.
As political pressure appears to mount on biotech stocks, some technical analysts say the foundation for a bounce may be building.
Three months after Wal-Mart said it would move faster to cut prices, Dollar General said it has taken a similar approach.
Europe's pursuit of companies like Apple for under-paid taxes highlights a major problem with few prospects for a global solution.
Call it crowd-sourcing for algorithmic trading.
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
Pacific Crest reiterates its overweight rating on Palo Alto Networks.
American banks spent the second quarter crying all the way to the, well, bank.
Shares of Mylan held slightly lower in afternoon trade, giving up earlier gains of more than 4 percent.
Shares of Workday climbed 7 percent after the enterprise software company reported an increase in subscriber revenue.
Dollar Tree and Dollar General reported same-store sales results that fell short of Wall Street's expectations.
Some of the names on the move ahead of the open.
The "Fast Money" traders share their first moves for the market open.
Sears posted a net loss and said it accepted debt financing of $300 million from Chief Executive Edward Lampert's hedge fund, ESL Investments.
Jim Cramer found astounding growth in one group, and thinks the theme is here to stay.
Shares of Teva Pharmaceuticals fell as much as 6 percent after the U.S. Patent Office invalidated two of the company's patents.
Get the best of CNBC in your inbox